Human lymphoblastoid cell lines: A goldmine for the biobankomics era

Pharmacogenomics

Volumn 12, Issue 6, 2011, Pages 907-917

  Nam, Hye Young ^a   Shim, Sung Mi ^a   Han, Bok Ghee ^a   Jeon, Jae Pil ^a  

^a National Biobank of Korea   (South Korea)

Author keywords

biobankomics; expression phenotype; immortalization; LCL

Indexed keywords

CARBOPLATIN; CISPLATIN; CYTARABINE; DAUNORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUVOXAMINE; METHOTREXATE; PACLITAXEL; PAROXETINE; PERFLUOROOCTANOIC ACID; SEROTONIN UPTAKE INHIBITOR; THAPSIGARGIN; TUNICAMYCIN;

ARTICLE; B LYMPHOCYTE; BIOBANKOMICS; BIOINFORMATICS; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG CYTOTOXICITY; DRUG SCREENING; EPSTEIN BARR VIRUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPHOBLASTOID CELL LINE; PHARMACOGENOMICS; PHENOTYPE; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOLOGICAL SPECIMEN BANKS; CELL LINE, TRANSFORMED; GENETIC VARIATION; HUMANS; KOREA; LYMPHOID PROGENITOR CELLS; PHENOTYPE;

EID: 79959472607     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.24     Document Type: Article

References (69)

1. Combon-Thomsen A: The social and ethical issues of post-genomic human biobanks. Nat. Rev. Genet. 5, 866-873 (2004).
2. Ozdemir V, Husereau D, Hyland S, Samper S, Salleh MZ: Personalized medicine beyond genomics: new technologies, global health diplomacy and anticipatory governance. Curr. Pharmacogenomics Person. Med. 7, 225-230 (2010).
3. Shin C, Abbott RD, Lee H, Kim J, Kimm K: Prevalence and correlates of orthostatic hypotension in middle-aged men and women in Korea: the Korean Health and Genome Study. J. Hum. Hypertens. 18, 717-723 (2004). (Pubitemid 39369192)
4. Lim S, Jang HC, Lee HK, Kimm KC, Park C, Cho NH: The relationship between body fat and C-reactive protein in middle-aged Korean population. Atherosclerosis 184, 171-177 (2006). (Pubitemid 41721085)
5. Cho YS, Go MJ, Kim YJ et al.: A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. Nat. Genet. 41, 527-534 (2009).
6. Yim SH, Kim TM, Hu HJ et al.: Copy number variations in east-Asian population and their evolutionary and functional implications. Hum. Mol. Genet. 19, 1001-1008 (2010).
7. Fortier I, Burton PR, Robson PJ et al.: Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. Int. J. Epidemiol. 39, 1383-1393 (2010).
8. Kim KJ, Lee HJ, Park MH et al.: SNP identification, linkage disequilibrium, and haplotype analysis for a 200-kb genomic region in a Korean population. Genomics 88(5), 535-540 (2006). (Pubitemid 44512071)
9. Yoo YK, Ke X, Hong S et al.: Fine-scale map of encyclopedia of DNA elements regions in the Korean population. Genetics 174(1), 491-497 (2006). (Pubitemid 44427689)
10. Jeon JP, Shim SM, Jung J et al.: A Comprehensive profile of DNA copy number variations in a Korean population: identification of copy number invariant regions among Koreans. Exp. Mol. Med. 41(9), 618-628 (2009).
11. HUGO Pan-Asian SNP Consortium; Abdulla MA, Ahmed I, Assawamakin A et al.: Mapping human genetic diversity in Asia. Science 326, 1541-1545 (2009).
12. Zhang W, Ratain MJ, Dolan ME: The HapMap resource is providing new insights into ourselves and its application to pharmacogenomics. Bioinformat. Biol. 2, 15-23 (2008).
13. Hutt-Fletcher LM: Epstein-Barr virus entry. J. Viol. 81, 7825-7832 (2007). (Pubitemid 47101468)
14. Burkitt D: A sarcoma involving the jaws in African children. Br. J. Surg. 46, 218-223 (1958).
15. Mideldorp M, Brink AA, van den Brule AJ, Meijer CJ: Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit. Rev. Oncol. Hematol. 45, 1-36 (2003) .16.
16. Kubuschok B, Schmits R, Hartmann F et al.: Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. Hum. Gene Ther. 13(7), 815-827 (2002). (Pubitemid 34493975)
17. Sun Q, Burton RL, Pollok LE, Emanuel DJ, Lucas KG: CD(+) Epstein-Barr virus-specific cytotoxic T-lymphocytes from human umbilical cord blood. Cell Immunol. 195(2), 81-88 (1999). (Pubitemid 29411571)
18. Okugawa K, Itoh T, Kawashima I et al.: Recognition of Epstein-Barr virus-associated gastric T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restriced 9-mer peptide. Oncol. Rep. 12(4), 725-731 (2004).
19. Hur DY, Lee MH, Kim JW et al.: CD19 signaling improves the Epstein-Barr virus-induced immortalization of human B cell. Cell Prolif. 38, 35-45 (2005). (Pubitemid 40229266)
20. Frisan T, Levitshy V, Masucci M: Generation of lymphoblastoid cell lines (LCLs). Methods Mol. Biol. 174, 125-127 (2001).
21. Gao J, Luo X, Tang K, Li X, Li G: Epstein-Barr virus integrate frequently into chromosome 4q,2q,1q and 7q of Burkitt's lymphoma cell line (Raji). J. Virol. Methods 136, 193-199 (2006). (Pubitemid 44051593)
22. Reisinger J, Rumpler S, Lion T, Ambros PF: Visualization of episomal and integrated Epstein-Barr virus DNA by fiber fluorescence in situ hybridization. Int. J. Cancer 118, 1603-1608 (2006). (Pubitemid 43376421)
23. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4(10), 757-768 (2004). (Pubitemid 39331148)
24. Jeon JP, Nam HY, Shim SM, Han BG: Sustained viral activity of Epstein-Barr virus contributes to cellular immortalization of lymphoblastoid cell lines. Mol. Cells 27, 143-148 (2009).
25. Bornkamm GW, Hammerschmidt W: Molecular virology of Epstein-Barr virus. Philos. Trans. R Soc. Lond. B Biol. Sci. 356, 437-459 (2001). (Pubitemid 32442745)
26. Eliopoulos AG, Young LS: LMP1 structure and signal transduction. Semin. Cancer Biol. 11, 435-444 (2001). (Pubitemid 33105022)
27. Mei YP, Zhu XF, Zhou JM, Huang H, Deng R, Zeng YX: siRNA targeting LMP1-induced apoptosis in EBV positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Lett. 232, 189-198 (2006). (Pubitemid 43170968)
28. Srinivas SK, Sixbey JW: Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J. Virol. 69, 8155-8158 (1995).
29. Zhang L, Hong K, Zhang J, Pagano JS: Multiple signal transducers and activators of transcription are induced by EBV LMP-1. Virology 323, 141-152 (2004). (Pubitemid 38681027)
30. Jeon JP, Kim JW, Park B et al.: Identification of tumor necrosis factor signaling-related proteins during Epstein-Barr virus-induced B cell transformation. Acta Virologica 52, 151-159 (2008).
31. Baik SY, Yun HS, Lee HJ et al.: Identification of stathmin 1 expression induced by Epstein-Barr virus in human B lymphocytes. Cell Prolif. 40, 268-281 (2007). (Pubitemid 46398818)
32. Jeon JP, Shim SM, Nam HY, Baik SY, Kim JW, Han BG: Copy number increase of 1p36.33 and mitochondrial genome amplification in Epstein-Barr virus-transformed lymphoblastoid cell lines. Cancer Genet. Cytogent. 173(2), 122-130 (2007).
33. Redon R, Ishikawa S, Fitch KR et al.: Global variation in copy number in the human genome. Nature 444, 444-454 (2006). (Pubitemid 44809057)
34. Brennan EP, Ehrich M, Brazil DP et al.: Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines. Epigenetics 4, 159-164 (2009).
35. Lee JE, Nam HY, Shim SM et al.: Expression phenotype changes of EBV-tranformed lymphoblastoid cell lines during long-term subculture and its clinical significance. Cell Prolif. 43, 378-384 (2010).
36. Lee JE, Hong EJ, Nam HY et al.: MicroRNA signatures associated with immortalization of EBV-transformed lymphoblastoid cell lines and their clinical traits. Cell Prolif. 44, 59-66 (2011).
37. Hartford CM, Dolan ME: Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 8, 1159-1168 (2007). (Pubitemid 47578225)
38. Welsh M, Mangravite L, Medina MW et al.: Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 61, 413-429 (2009).
39. Li L, Fridley BL, Kalari K et al.: Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS ONE 4(11), e7765 (2009).
40. Cheung VG, Spilman RS, Ewens KG, Weber TM, Morley M, Burdick JT: Mapping determinants of human gene expression by regional and genome-wide association. Nature 437, 1365-1369 (2005). (Pubitemid 41568683)
41. Stranger BE, Forrest MS, Clark AG et al.: Genome-wide associations of gene expression variation in humans. PLoS Genet. 1, e78 (2005).
42. Stranger BE, Nica AC, Forrest MS et al.: Population genomics of human gene expression. Nat. Genet. 39, 1217-1224 (2007). (Pubitemid 47482691)
43. Dixon AL, Liang L, Moffatt MF et al.: A genome-wide association study of global gene expression. Nat. Genet. 39, 1202-1207 (2007). (Pubitemid 47482680)
44. Niu N, Qin Y, Fridley BL et al.: Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 20, 1482-1492 (2010).
45. Dombroski BA, Nayak RR, Ewens KG et al.: Gene expression and genetic variation in response to endoplasmic reticulum stress in human cells. Am. J. Hum. Genet. 86, 719-729 (2010).
46. Walgren RA, Meucci MA, McLeod HL: Pharmacogenomic discovery approaches: will the real genes please stand up? J. Clin. Oncol. 23, 7342-7349 (2005). (Pubitemid 46202347)
47. Zhang W, Dolan ME: Use of cell lines in the investigation of pharmacogenetic loci. Curr. Pharm. Des. 15(32), 3782-3795 (2009).
48. Sie L, Loong S, Tan EK: Utility of lymphoblastoid cell lines. J. Neurosci. Res. 87, 1953-1959 (2009).
49. Sawada K, Noda K, Nakajima H, Shimbara N, Furuichi Y, Sugimoto M: Differential cytotoxicity of anticancer agents in pre- and post-immortal lymphoblastoid cell lines. Biol. Pharm. Bull. 28, 1202-1207 (2005). (Pubitemid 41327586)
50. Markasz L, Stuber G, Flaberg E et al.: Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblstoid B-cells. BMC Cancer 13(6), 265 (2006).
51. Hartford CM, Duan S, Delaney SM et al.: Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113, 2145-2153 (2009).
52. Huang RS, Duan S, Shukla SJ et al.: Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81, 427-437 (2007). (Pubitemid 47330203)
53. Huang RS, Duan S, Bleibel WK et al.: A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl. Acad. Sci. USA 104, 9758-9763 (2007). (Pubitemid 47175340)
54. Duan S, Bleibel WK, Huang RS et al.: Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res. 67, 5425-5433 (2007). (Pubitemid 46997283)
55. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME: Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum. Genomics 3(2), 128-142 (2009).
56. O'Shea SH, Schwarz J, Kosyk O et al.: In vitro screening for population variability in chemical toxicity. Toxicol. Sci. 119, 398-407 (2011).
57. Smirnov DA, Morley M, Shin E, Spielman RS, Cheung VG: Genetic analysis of radiation-induced changes in human gene expression. Nature 459(7246), 587-591 (2009).
58. Morag A, Kirchheiner J, Rehavi M, Gurwitz D: Human lymphoblastoid cell line panels: novel tools for assessing shared drug pathways. Pharmacogenomics 11(3), 327-340 (2010).
59. Fry RC, Svensson JP, Valiathan C et al.: Genomic predictors of interindividual differences in response to DNA damaging agents. Genes Devel. 22, 2621-2626 (2008).
60. Akey JM, Biswas S, Leek JT, Storey JD: On the design and analysis of gene expression studies in human populations. Nat. Genet. 39, 807-808 (2007). (Pubitemid 47014480)
61. Choy E, Yelensky R, Bonakdar S et al.: Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 4(11), E1000287 (2008).
62. Lacoste S, Wiechec E, Silva AG et al.: Chromosomal rearrangements after ex vivo Epstein-Barr virus (EBV) infection of human B cells. Oncogene 29, 503-515 (2010).
63. Shukla SJ, Dolan ME: Use of CEPH and non-CEPH lymphoblast cell lines in pharmacogenetic studies. Pharmacogenomics 6(3), 303-310 (2005). (Pubitemid 40601633)
64. Sugimoto M, Tahara H, Ide T, Furuichi Y: Steps involved in immortalization and tumorigenesis in human B lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res. 64, 3361-3364 (2004). (Pubitemid 38657904)
65. Zhang W, Duan S, Kistner EO et al.: Evaluation of genetic variation contributing to differences in gene expression between populations. Am. J. Hum. Genet. 82, 631-640 (2008).
66. Cheung VG, Conlin LK, Teresa M et al.: Natural variation in human gene expression assessed in lymphoblastoid cells. Nat. Genet. 33, 422-425 (2003). (Pubitemid 36278862)
67. Emilsson V, Thorleifsson G, Zhang B et al.: Genetics of gene expression and its effect on disease. Nature 452, 423-430 (2008).
68. Ding J, Gudjonsson JE, Liang L et al.: Gene expression in skin and lymphoblastoid cells: refined statistical method reveals extensive overlap in cis-eQTL signals. Am. J. Hum. Genet. 87, 779-789 (2010).
69. Jen KY, Cheung VG: Transcriptional response of lymphoblastoid cells to ionizing radiation. Genome Res. 13, 2092-2100 (2003). (Pubitemid 37161766)